NCT03503149Recruiting
Molecular Tumor Board at the Center for Personalized Medicine Tübingen
Molecular Tumor Board at the Center for Personalized Medicine Tübingen: a Prospective Observational Study
Source: ClinicalTrials.gov · Last updated 19 Apr 2018 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Molecular Tumor Board at the Center for Personalized Medicine
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 23 Mar 2018
- Start date
- 1 Mar 2018
- Primary completion date
- 1 Mar 2028
- Lead sponsor
- University Hospital Tuebingen
- Diseases
- Childhood cancers
- NCT number
- NCT03503149
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 1 Mar 2018 to the primary completion date, 1 Mar 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- The MTB assists the referring physician with the interpretation and the use of tumor molecular profiling data for deciding on a therapeutic strategy. Therefore, this board is confined to cancer patients and cannot provide any service for non-cancer patients
Who the study is looking for
- Given informed consent ("broad consent" of the University Hospital Tübingen)
- ≥ 18 years of age
- Clinical indication for a referral to Molecular Tumor Board by the treating physician
Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Tübingen Coordinator of this site? Confirm its status | Tübingen | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.